Vertex Pharmaceuticals and British health authorities have been stuck in cystic fibrosis (CF) drug pricing negotiations for years, and now those talks have again heated up. National Health Service ...

Hundreds of people with the most common type of cystic fibrosis could be offered a new triple therapy after the National Institute for Health and Care Excellence (NICE) recommended ...

Vertex Pharmaceuticals has reached a pricing deal for its cystic fibrosis drugs with the National Health Service in England, ending a yearslong campaign by patients to secure access to the medicines.

A young girl with cystic fibrosis whose lungs were functioning at just 67 percent is running around again thanks to a miracle drug recently added to the NHS funding list. Harriet Corr, seven, is ...

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an extended long-term reimbursement agreement with NHS England providing ...

A years-long cystic fibrosis drug pricing standoff has finally yielded a deal, and now thousands of patients in the U.K. are set to access key medicines from Vertex Pharmaceuticals. Vertex and NHS ...

After months of uncertainty, Vertex Pharmaceuticals (NASDAQ:VRTX) on Thursday announced a long-term reimbursement agreement with England’s National Health Service (NHS) for its drugs targeted at a ...

After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a long-running saga ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...